Review article
Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder
Evidencia disponible acerca del uso del agonista β3-adrenoceptor selectivo mirabegrón para el tratamiento de la vejiga hiperactiva
a Servicio de Urología, Hospital Universitario de Getafe, Madrid, Spain
b Servicio de Ginecología, St Mary's Hospital, Imperial College, Londres, United Kingdom
c Servicio de Urología, New York University Langone Medical Center, Nueva York, United States
d Departamento Médico, Astellas Pharma Europe Ltd, Chertsey and Department of Urology, Ealing Hospital, Londres, United Kingdom
Read
1132
Timeswas read the article
302
Total PDF
830
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2019 10 | 1 | 0 | 1 |
| 2018 3 | 4 | 0 | 4 |
| 2018 2 | 27 | 3 | 30 |
| 2018 1 | 14 | 0 | 14 |
| 2017 12 | 26 | 1 | 27 |
| 2017 11 | 22 | 6 | 28 |
| 2017 10 | 32 | 2 | 34 |
| 2017 9 | 18 | 4 | 22 |
| 2017 8 | 22 | 9 | 31 |
| 2017 7 | 20 | 2 | 22 |
| 2017 6 | 32 | 9 | 41 |
| 2017 5 | 35 | 1 | 36 |
| 2017 4 | 34 | 9 | 43 |
| 2017 3 | 32 | 29 | 61 |
| 2017 2 | 50 | 1 | 51 |
| 2017 1 | 14 | 2 | 16 |
| 2016 12 | 37 | 15 | 52 |
| 2016 11 | 47 | 9 | 56 |
| 2016 10 | 53 | 11 | 64 |
| 2016 9 | 45 | 8 | 53 |
| 2016 8 | 26 | 12 | 38 |
| 2016 7 | 19 | 5 | 24 |
| 2016 6 | 19 | 9 | 28 |
| 2016 5 | 16 | 24 | 40 |
| 2016 4 | 23 | 20 | 43 |
| 2016 3 | 32 | 22 | 54 |
| 2016 2 | 30 | 24 | 54 |
| 2016 1 | 36 | 17 | 53 |
| 2015 12 | 22 | 15 | 37 |
| 2015 11 | 13 | 9 | 22 |
| 2015 10 | 0 | 1 | 1 |
| 2015 9 | 0 | 2 | 2 |
| 2015 2 | 0 | 1 | 1 |
| 2014 12 | 0 | 1 | 1 |
| 2014 9 | 0 | 1 | 1 |
| 2014 3 | 0 | 1 | 1 |
| 2014 2 | 0 | 1 | 1 |
| 2014 1 | 13 | 8 | 21 |
| 2013 12 | 16 | 8 | 24 |
Show all
